Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states

Brain Research

Volumn 1197, Issue , 2008, Pages 135-142

  Schmid, Adrien W ^a   Freir, Darragh B ^a   Herron, Caroline E ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Beta amyloid peptide; CA1 region; Hippocampus; In vivo; Long term potentiation

Indexed keywords

AMYLOID BETA PROTEIN; CONGO RED; THIOFLAVINE;

ANIMAL EXPERIMENT; ARTICLE; BETA SHEET; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FACILITATION; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; POST TETANIC POTENTIATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; RAT; SYNAPTIC TRANSMISSION;

AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CONGO RED; INJECTIONS, INTRAVENTRICULAR; LONG-TERM POTENTIATION; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, WISTAR; SYNAPTIC TRANSMISSION; THIAZOLES;

EID: 39149109592     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.11.056     Document Type: Article

References (50)

1. Asztely F., Hanse E., and Gustafsson B. The early decay of long-term potentiation in the hippocampal CA1 region in vitro is reduced by activators of protein kinase C. Brain Res. 521 (1990) 355-358
2. Bitan G., Lomakin A., and Teplow D.B. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276 (2001) 35176-35184
3. Bush A.I., Pettingell Jr. W.H., Paradis M.D., and Tanzi R.E. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269 (1994) 12152-12158
4. Costello D.A., and Herron C.E. The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 46 (2004) 655-662
5. Chen Q.S., Kagan B.L., Hirakura Y., and Xie C.W. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J. Neurosci. Res. 60 (2000) 65-72
6. Clements A., Walsh D.M., Williams C.H., and Allsop D. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide. Neurosci. Lett. 161 (1993) 17-20
7. Crystal A.S., Giasson B.I., Crowe A., Kung M.P., Zhuang Z.P., Trojanowski J.Q., and Lee V.M. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86 (2003) 1359-1368
8. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. NeuroReport 8 (1997) 3213-3217
9. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., and Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280 (2005) 17294-17300
10. Engstrom I., Ronquist G., Pettersson L., and Waldenstrom A. Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. Eur. J. Clin. Invest. 7 (1995) 471-476
11. Fraser P.E., Nguyen J.T., Surewicz W.K., and Kirschner D.A. pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60 (1991) 1190-1201
12. Freir D.B., and Herron C.E. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Res. 967 (2003) 27-36
13. Freir D.B., Holscher C., and Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 85 (2001) 708-713
14. Freir D.B., Costello D., and Herron C.E. A beta 25-35-induced depression of long-term potentiation in area CA1 in vivo and in vitro is attenuated by verapamil. J. Neurophysiol. 89 (2003) 3061-3069
15. Frick A., Magee J., and Johnston D. LTP is accompanied by an enhanced local excitability of pyramidal neuron dendrites. Nat. Neurosci. 7 (2004) 126-135
16. Frid P., Anisimov S.V., and Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res. Rev. 53 (2007) 135-160
17. Gengler S., Gault V.A., Harriot P., and Holscher C. Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background. Exp. Brain Res. 561 (2007) 85-90
18. Good T.A., and Murphy R.M. Effect of beta-amyloid block of the fast-inactivating K+ channel on intracellular Ca2+ and excitability in a modelled neuron. Proc. Natl. Acad. Sci. 93 (1996) 15130-15135
19. Harper J.D., Wong S.S., Lieber C.M., and Lansbury Jr. P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38 (1991) 8972-8980
20. Huang T.H., Yang D.S., Plaskos N.P., Go S., Yip C.M., Fraser P.E., and Chakrabartty A. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297 (2000) 73-87
21. Huber K.M., Gallagher S.M., Warren S.T., and Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. 99 (2002) 7746-7750
22. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
23. Jacobsen S., Wu C.-.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., and Bloom F. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. 103 (2006) 5161-5166
24. Kad N.M., Myers S.L., Smith D.P., Smith D.A., Radford S.E., and Thomson N.H. Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy. J. Mol. Biol. 330 (2003) 785-797
25. Kawamura Y., Manita S., Nakamura T., Inoue M., Kudo Y., and Miyakawa H. Glutamate release increases during mossy-CA3 LTP but not during Schaffer-CA1 LTP. Eur. J. Neurosci. 19 (2004) 1591-1600
26. Klug G.M., Losic D., Subasinghe S.S., Aguilar M.I., Martin L.L., and Small D.H. Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. Eur. J. Biochem. 270 (2003) 4282-4293
27. Klyubin I., Walsh D.M., Cullen W.K., Fadeeva J.V., Anwyl R., Selkoe D.J., and Rowan M.J. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur. J. Neurosci. 19 (2004) 2839-2846
28. Klunk W.E., Pettegrew J.W., and Abraham D.J. Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37 (1989) 1273-1281
29. Kowalewski T., and Hotzmann DM. In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc. Natl. Acad. Sci. 96 (1999) 3688-3693
30. Krebs M.R.H., Bromley E., and Donald A.M. The binding of thioflavin T to amyloid fibrils: localization and implications. J. Struct. Biol. 149 (2005) 30-37
31. Lisman J., Schulman H., and Cline H. The molecular basis of CaMKII function in synaptic and behavioural memory. Nat. Rev., Neurosci. 3 (2002) 175-190
32. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12243-12247
33. Lorton D., Kocsis J.M., King L., Madden K., and Brunden K.R. Beta-amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes. J. Neuroimmunol. 67 (1996) 21-29
34. Mattson M.P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77 (1997) 1081-1132
35. Morgan S.L., and Teyler T.J. VDCCs and NMDARs underlie two forms of LTP in CA1 hippocampus in vivo. J. Neurophysiol. 82 (1999) 736-740
36. Naiki H., and Nakakuki K. First-order kinetic model of Alzheimer's beta-amyloid fibril extension in vitro. Lab. Invest. 74 (1996) 374-383
37. Nakagami Y., Nishimura S., Murasugi T., Kaneko I., Meguro M., Marumoto S., Kogen H., Koyama K., and Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br. J. Pharmacol. 137 (2002) 676-682
38. Parameshwaran K., Sims C., Kanju P., Vaithianathan T., Shonesy B.C., Dhanasekaran M., Bahr B.A., and Suppiramaniam V. Amyloid beta-peptide Abeta(1-42) but not Abeta(1-40) attenuates synaptic AMPA receptor function. Synapse 61 (2007) 367-374
39. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur. J. Pharmacol. 207 (1991) 367-368
40. Raymond C.R., Ireland D.R., and Abraham W.C. NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res. 968 (2003) 263-272
41. Schulz P.E., Cook E.P., and Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J. Neurosci. 14 (1994) 5325-5337
42. Stephan A., Laroche S., and Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21 (2001) 5703-5714
43. Tjernberg L.O., Callaway D.J., Tjernberg A., Hahne S., Lilliehook C., Terenius L., Thyberg J., and Nordstedt C. A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 274 (1999) 12619-12625
44. Walsh D.M., Hartley D.M., Kusumoto Y., Fezoui Y., Condron M.M., Lomakin A., Benedek G.B., Selkoe D.J., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274 (1999) 25945-25952
45. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
46. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002) 552-557
47. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., Viola K.L., Klein W.L., Stine W.B., Krafft G.A., and Trommer B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924 (2002) 133-140
48. Wang Q., Rowan M.J., and Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci. 24 (2004) 6049-6056
49. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., and Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24 (2004) 3370-3378
50. Ye C., Walsh D.M., Selkoe D.J., and Hartley D.M. Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-d-aspartate (NMDA) versus non-NMDA receptor/channel activation. Neurosci. Lett. 366 (2004) 320-325